Pharmaceuticals, Biotechnology and Life Sciences
Nearly 70 abstracts, including more than 20 oral presentations highlight diverse portfolio of innovative treatment modalities, including potentially transformative cell…
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced…
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and…
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from…
Five abstracts to be presented on the pre-clinical and clinical results, demonstrating the breadth and versatility of the Company’s allogeneic,…
Three oral presentations to feature analyses from global pivotal phase 3 QuANTUM-R study of quizartinib Updated phase 1 study results…
—Rocket Management to Hold a Breakout Session with KOLs to Discuss Data Following Presentation at 8:30 p.m. EST on December…
BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data…
MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune…
— First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in…